Related Experiment Video
Updated: Apr 13, 2026

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions
Published on: June 13, 2025
5-Bromocytidine protects against hyperuricemia-induced renal injury by suppressing TLR4/NF-κB-mediated inflammation
Menghan Wang1, Liang Han1, Dong Tian1
1Department of Pharmacy, Lanzhou University, Lanzhou, 730000, PR China.
Abstract:
Hyperuricemia (HUA), a prevalent metabolic disorder, is an independent risk factor for chronic kidney disease (CKD). Elevated serum uric acid (UA) level leads to renal UA deposition, causing kidney inflammation, impairing renal function, and accelerating HUA progression. In this study, an inflammation model in RAW264.7 cells induced by monosodium urate (MSU) was established to screen for compounds resistant to MSU-induced inflammation. Fortunately, 5-bromocytidine, a nucleic acid analogue, demonstrated potent anti-inflammatory activity in MSU-treated RAW264.7 cells and exhibited excellent therapeutic effects in HUA rats by reducing serum UA, creatinine (CRE) and blood urea nitrogen (BUN) amounts. Furthermore, we found that 5-bromocytidine blocked the activation of TLR4/NF-κB signaling pathway which mediated inflammation, and downregulated the expression of IL-1β and NLRP3. In summary, 5-bromocytidine may ameliorate HUA by suppressing the renal TLR4/NF-κB signaling pathway, suggesting a new candidate compound for HUA therapy.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Urinary Tract Calculi IV: Nutrition Therapy and Prevention

